All News #Library
Quality
Mesoblast CEO takes 30% pay cut to fund 3rd shot at FDA approval
30 Aug 2023 //
FIERCE BIOTECH
FDA rejects Mesoblast`s cell therapy for bone marrow transplant complications
04 Aug 2023 //
GLOBENEWSWIRE
FDA Schedules Pre-License Inspection of Remestemcel-L Manufacturing
21 Mar 2023 //
GLOBENEWSWIRE

Market Place
Sourcing Support